Skip to content

Comparison of effect of methadone and methadone adjuvant Olanzapine on treatment in heroin and methamphetamine dependents with Novelty seeking temperament

Comparison of the effectiveness of methadone and temperament-based pharmacotherapy on treatment retention, relapse, and treatment boredom in heroin and methamphetamine dependents

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20230914059433N1
Enrollment
42
Registered
2023-10-12
Start date
2023-04-04
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: methamphetamine dependents. Condition 2: heroin dependents. Adverse effect of amphetamines Poisoning by and adverse effect of heroin

Interventions

Intervention 1: Intervention group:Methadon meintenance therapy adjuctive temprament-based psychopharmacotherapy with 5-10 mg olanzapine orally daily .In this group, people are treated with methadone

Sponsors

Arak University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Consent to participate in the study All dependent patients on heroin and meth-amphetamine Having Novelty seeking temperament Age 18 to 45 years Having desire to methadone maintenance treatment

Exclusion criteria

Exclusion criteria: Having past history of medical complication after use antipsychotic Having past history of Renal and liver disease Having past history of Heart disease

Design outcomes

Primary

MeasureTime frame
Boredom. Timepoint: 6 months. Method of measurement: Boredom questionnaire.;Relapse. Timepoint: 6 months. Method of measurement: Urine anlysis.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRastibarzoki Akram

Arak University of Medical Sciences

akrmrastybrzky@gmail.com+98 86 3313 7948

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026